FOXP3 and immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome: These results clearly indicate that an HSC-based gene therapy approach for IPEX disease is not feasible by gene addiction but rather needs FOXP3 gene replacement preserving endogenous regulation of expression.